SCHEMBL3475869

SCHEMBL3475869

CN(C)C=CC(=O)c1ccc(Br)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 1.00
KDM4E B2RXH2 2/20 1.00
KMT2A Q03164 2/20 1.00
GAA P10253 1/20 0.66
RAB9A P51151 5/20 0.53
RECQL P46063 2/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 2/20 0.53
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
DAO P14920 1/20 0.48
MAPT P10636 6/20 0.48
NPC1 O15118 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
GSK3B P49841 2/20 0.47
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
HTT P42858 1/20 0.45
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978870 1.00 ALDH1A1 (1.00) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL7476495 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL2196627 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL14007054 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL13992611 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL2196629 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL7476500 0.81 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL3516805 0.79 ALDH1A1 (1.00) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL2984666 0.77 ALDH1A1 (0.62) ALDH1A1KDM4EKMT2AGAARAB9A
SCHEMBL2984669 0.77 ALDH1A1 (0.62) ALDH1A1KDM4EKMT2AGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-7470701-B2 Substituted 2,5-heterocyclic derivatives NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 US disclosed
US-20080255120-A1 SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255120-A1 SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES CYP3A5, ABCG2, ABCB1 ALDH1A1 297/4885KDM4E 2840/4885KMT2A 4030/4885
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 ALDH1A1 1487/4885KDM4E 1934/4885KMT2A 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.